Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00835666 · ClinicalTrials.gov registry record · Phase 1

Finasteride 5 mg Tablets Under Fasting Conditions

A Phase 1 study, sponsored by Teva Pharmaceuticals USA.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target

NCT00835666: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.

NCT00835666 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00835666, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target

Study Summary

The objective of this study is to compare the relative bioavailability of finasteride 5 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of PROSCAR® 5 mg tablets (Merck) in healthy, adult, non-smoking, male subjects under fasting conditions.

Primary Outcome

Bioequivalence based on Cmax

Interventions

  • DRUG Finasteride 5 mg tablets
  • DRUG PROSCAR®

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2002-06
Est. Completion 2002-06
Phase Phase 1
Teva Pharmaceuticals USA

83 total trials

What the finished NCT00835666 record still lists

NCT00835666 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).

The record links to 0 conditions, and to 2 interventions - of which Finasteride 5 mg tablets is the first listed.

NCT00835666 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00835666 about?

NCT00835666 is a clinical study titled "Finasteride 5 mg Tablets Under Fasting Conditions". The objective of this study is to compare the relative bioavailability of finasteride 5 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of PROSCAR® 5 mg tablets (Merck) in healthy, adult, non-smoking, male subjects under fasting conditions.

What is the current status of trial NCT00835666?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2002-06. Estimated completion is 2002-06.

What interventions are being tested in trial NCT00835666?

The interventions under investigation include: Finasteride 5 mg tablets (DRUG), PROSCAR® (DRUG).

Who is sponsoring clinical trial NCT00835666?

This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00835666's enrollment target sits among peer trials

32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00835666, the US trial registry maintained by the National Library of Medicine. NCT00835666 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.